Modulation of monocyte-tumour cell interactions by Mycobacterium vaccae

Cancer Immunology, Immunotherapy

Volumn 53, Issue 12, 2004, Pages 1127-1134

  Baran, Jarosaw ^a   Baj Krzyworzeka, Monika ^a   Wȩglarczyk, Kazimierz ^a   Ruggiero, Irena ^a   Zembala, Marek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cancer cells; Cytokines; Deactivation; Monocytes; Mycobacterium vaccae

Indexed keywords

BCG VACCINE; CANCER VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIAL STRAIN; CELL INTERACTION; CELL STIMULATION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; MONOCYTE; MYCOBACTERIUM VACCAE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; TUMOR CELL;

CELL COMMUNICATION; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-12; MONOCYTES; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8644289973     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0552-6     Document Type: Article

References (32)

1. Assersohn L, Souberbielle BE, O'Brien ME, Archer CD, Mendes R, Bass R, Bromelow KV, Palmer RD, Bouilloux E, Kennard DA, Smith IE (2002) A randomized pilot study of SRL 172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Clin Oncol 14:23
2. Benkhart EM, Siedlar M, Wedel A, Werner T, Ziegler-Heitbrock HWL (2000) Role of Stat3 in lipopolysaccharide-induced IL-10 gene expression. J Immunol 165:1612
3. Clerici B, Enrico E, Shearer G (1996) Tumour enhancement phenomenon: reinterpretation from a Th1/Th2 perspective. J Natl Cancer Inst 88:461
4. Elgert KD, Alleva DG, Mullins DW (1998) Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64:275
5. Hrouda D, Baban B, Dunsmuir W, Kirby R, Dalgleish AG (1998) Immunotherapy of advanced prostate cancer: a phase I/ II trial using Mycobacterium vaccae (SRL172). Br J Urol 82:568
6. Jones BW, Means TK, Heldwein KA, Keen MA, Hill PJ, Belisle JT, Fenton MJ (2001) Different Toll-like receptor agonists induce distinct macrophage responses. J Leukoc Biol 69:1036
7. Kremer L, Estaquier J, Brandt E, Ameisen JC, Locht C (1997) Mycobacterium bovis Bacillus Calmette-Guerin infection preapoptosis of resting human monocytes. Eur J Immunol 27:2450
8. Kurisu H, Matsuyama H, Ohmoto Y, Shimabukuro T, Naito K (1994) Cytokine-mediated antitumor effect of bacillus Calmette-Guerin on tumor cells in vitro. Cancer Immunol Immunother 39:249
9. Lamm DL (1992) Optimal BCG treatment of superficial bladder cancer as defined by American trails. Eur Urol 21[Suppl 2]: 12
10. Li Q, Verma IM (2002) NF-κB regulation in the immune system. Nat Rev Immunol 2:725
11. Mantovani A, Sozzani S, Massimo L, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549
12. Maraveyas A, Baban B, Kennard D, Rook GA, Westby M, Grange JM, Lydyard P, Stanford JL, Jones M, Selby P, Dalgleish AG (1999) Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 10:817
13. Matsumoto M, Seya T, Kikkawa S, Tsuji S, Shida K, Nomura M, Kurita-Taniguchi M, Ohigashi H, Yokouchi H, Takami K, Hayashi A, Azuma I, Masaoka T, Kodama K, Toyoshima K, Higashiyama M (2001) Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton. Int Immunopharmacol 8:1559
14. Mendes R, O'Brien MER, Mitra A, Norton A, Gregory RK, Padhani AR, Bromelow KV, Winkley AR, Ashley S, Smith IE, Souberbielle BE (2002) Clinical and immunological assessment of Mycobacterium vaccae (SRL 172) with chemotherapy in patients with malignant mesothelioma. Br J Cancer 86:336
15. Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumours. J Urol 116:180
16. Mytar B, Siedlar M, Wooszyn M, Ruggiero I, Pryjma J, Zembala M (1999) Induction of reactive oxygen intermediates in human monocytes by tumour cells and their role in spontaneous monocyte cytotoxicity. Br J Cancer 79:737
17. Mytar B, Siedlar M, Wooszyn M, Colizzi V, Zembala M (2001) Cross-talk between human monocytes and cancer cells during reactive oxygen intermediates generation: the essential role of hyaluronan. Int J Cancer 94:727
18. Mytar B, Wooszyn M, Szatanek R, Baj-Krzyworzeka M, Siedlar M, Ruggiero I, Wiçckiewicz J, Zembala M (2003) Tumor cell-induced deactivation of human monocytes. J Leukoc Biol 74:1094
19. Nicholson S, Guile K, John J, Clarke IA, Diffley J, Donnellan P, Michael A, Szlosarek P, Dalgleish AG (2003) A randomized phase II trial of SRL 172 (Mycobacterium vaccae) ± low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res 13:389
20. O'Brien ME, Saini A, Smith IE, Webb A, Gregory K, Mendes R, Ryan C, Priest K, Bromelow KV, Palmer RD, Tuckwell N, Kennard DA, Souberbielle BE (2000) A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Brit J Cancer 83:853
21. Popiela T, Zembala M, Oszacki J, Jȩdrychowski W (1982) A follow-up study on chemoimmunotherapy (5-fluorouracil and BCG) in advanced gastric cancer. Cancer Immunol Immunother 13:182
22. Portelance V, Boulanger RP, Duranleau-Dragon D (1976) Comparative virulence and antitumor activity of BCG substrains. In: Lamoureux G, Turcotte R, Portelance V (eds) BCG in cancer immunotherapy. Grune and Stratton, New York, pp 5-13
23. Pryor K, Goddard J, Goldstein D, Stricker P, Russell P, Golovsky D, Penny R (1995) Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer 71:801
24. Sedlaczek L, Lisowska K, Korycka M, Rumijowska A, Ziókowski A, Dugoński J (1999) The effect of cell wall components on glycine-enhanced sterol side chain degradation to androstene derivatives by mycobacteria. Appl Microbiol Biotechnol 52:563
25. Sica A, Saccani A, Botazzi B, Polentaruti N, Vecchi A, van Damme J, Mantovani A (2000) Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 164:762
26. Skinner M, Yuan S, Prestidge R, Chuk D, Watson J, Tan P (1997) Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun 65:4525
27. Stanford JL, Rook GA, Bahr GM, Dowlati Y, Ganapati R, Ghazi Sai K, Lucas S, Ramu G, Torres P, Minh Ly H et al (1990) Mycobacterium vaccae in immuniprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine 8:525
28. Tian X, Groves M (1999) Formulation and biological activity of antineoplastic proteoglycans derived from Mycobacterium vaccae in chitosan nanoparticles. J Pharm Pharmacol 51:151
29. Uehori J, Matsumoto M, Tsuji S, Akazawa T, Takeuchi O, Akira S, Kawata T, Azuma I, Toyoshima K, Seya T (2003) Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guerin peptidoglycan. Infect Immun 71:4238
30. Wang C, Rook G (1998) Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology 93:307
31. Zembala M, Czupryna A, Wieckiewicz J, Jasinski M, Pryjma J, Ruggiero I, Siedlar M, Popiela T (1993) Tumour-cell-induced production of tumour necrosis factor by monocytes of gastric cancer patients receiving BCG immunotherapy. Cancer Immunol Immunother 36:127
32. Zembala M, Siedlar M, Ruggiero I, Wieckiewicz J, Mytar B, Mattei M, Colizzi V (1994) The MHC class-II and CD44 molecules are involved in the induction of tumour necrosis factor (TNF) gene expression by human monocytes stimulated with tumour cells. Int J Cancer 56:269